Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Tenax Therapeutics, Inc. (NASDAQ:TENX) has become one of the more unusual biotechnology special situations of August.</li><li>The company is developing oral levosimendan for pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF, a difficult cardiovascular condition with no approved therapy specifically targeting this population.</li><li>On August 10, the investment case appeared to break.</li></ul>

Tenax Therapeutics, Inc. (NASDAQ:TENX) has become one of the more unusual biotechnology special situations of August.The company is developing oral levosimendan for pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF, a difficult cardiovascular condition with no approved therapy specifically targeting this population.On August 10, the investment case appeared to break.

Tenax Therapeutics: Adar1 Bought $1.8 Million After The Phase 3 Collapse — What Could It Be Seeing Before ESC?

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
  <li>
<a href="https://smartkarma.com/entities/tenax-therapeutics-inc">Tenax Therapeutics </a>is a clinical-stage pharmaceutical company focused on developing and commercializing therapies for cardiovascular and pulmonary diseases with high unmet medical needs.</li>
  <li>The company's lead product candidates are TNX-103 (oral levosimendan) for the treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) and TNX-201 (a modified-release oral formulation of imatinib) for Pulmonary Arterial Hypertension (PAH).</li>
  <li>Recent clinical trial progress for TNX-103, including achieving the randomization target for the Phase 3 LEVEL study, represents a significant potential value inflection point for the company, with topline data expected in the third quarter of 2026.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
Tenax Therapeutics is a clinical-stage pharmaceutical company focused on developing and commercializing therapies for cardiovascular and pulmonary diseases with high unmet medical needs.
  The company's lead product candidates are TNX-103 (oral levosimendan) for the treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) and TNX-201 (a modified-release oral formulation of imatinib) for Pulmonary Arterial Hypertension (PAH).
  Recent clinical trial progress for TNX-103, including achieving the randomization target for the Phase 3 LEVEL study, represents a significant potential value inflection point for the company, with topline data expected in the third quarter of 2026.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Tenax Therapeutics  (TENX US) - Apr 2026

Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

<ul><li>Tenax has licensed the calcium sensitizer/K-ATP activator levosimendan and is pursuing approval for an indication in Group 2 Pulmonary Hypertension in the US and Canada.</li><li>The drug has been approved in over 60 countries with 35 published trials supporting its safety and efficacy and has over 1 million patient exposures.</li><li> In January 2018 Tenax announced a new indication for Levo and met with the FDA to confirm trial design.</li></ul>

Tenax has licensed the calcium sensitizer/K-ATP activator levosimendan and is pursuing approval for an indication in Group 2 Pulmonary Hypertension in the US and Canada.The drug has been approved in over 60 countries with 35 published trials supporting its safety and efficacy and has over 1 million patient exposures. In January 2018 Tenax announced a new indication for Levo and met with the FDA to confirm trial design.

United States

Tenax Therapeutics, Inc. operates as a specialty pharmacuitical company. The Company develops and commercializes products for the critical care market. Tenax Therapeutics develops treatments for treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF) using levosimendan.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Tenax Therapeutics (TENX US)

Tenax Therapeutics: Adar1 Bought $1.8 Million After The Phase 3 Collapse — What Could It Be Seeing Before ESC?

Tenax Therapeutics, Inc. (NASDAQ:TENX) has become one of the more unusual biotechnology special situations of August. The company is developing...

Baptista Research

Primer: Tenax Therapeutics (TENX US) - Apr 2026

Tenax Therapeutics is a clinical-stage pharmaceutical company focused on developing and commercializing therapies for cardiovascular and...

αSK Primers

TENX: 100 Million Capital Raise

Tenax has licensed the calcium sensitizer/K-ATP activator levosimendan and is pursuing approval for an indication in Group 2 Pulmonary...

Zacks Small Cap Research

TENX: First Quarter Results

Tenax has licensed the calcium sensitizer/K-ATP activator levosimendan and is pursuing approval for an indication in Group 2 Pulmonary...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)